144 related articles for article (PubMed ID: 7490678)
21. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer.
Zhuang Z; Merino MJ; Chuaqui R; Liotta LA; Emmert-Buck MR
Cancer Res; 1995 Feb; 55(3):467-71. PubMed ID: 7834608
[TBL] [Abstract][Full Text] [Related]
22. Mutation at chromosome 11q23 in human non-familial breast cancer: a microdissection microsatellite analysis.
Koreth J; Bethwaite PB; McGee JO
J Pathol; 1995 May; 176(1):11-8. PubMed ID: 7616353
[TBL] [Abstract][Full Text] [Related]
23. Alterations of p53 gene in primary gastric cancer tissues.
Hong SI; Hong WS; Jang JJ; Lee DS; Cho NS; Jung ME; Kim HB; Ha GW; Park IC; Cho DS
Anticancer Res; 1994; 14(3B):1251-5. PubMed ID: 8067692
[TBL] [Abstract][Full Text] [Related]
24. [Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer].
Iwase H; Kobayashi S; Iwata H; Yamashita T; Ito K; Toyama T; Hara Y; Greenman J; Mathew CG
Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():61-5. PubMed ID: 8702313
[TBL] [Abstract][Full Text] [Related]
25. 3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy.
Sanz-Ortega J; Saez MC; Sierra E; Torres A; Balibrea JL; Hernando F; Sanz-Esponera J; Merino MJ
J Pathol; 2001 Nov; 195(4):429-34. PubMed ID: 11745674
[TBL] [Abstract][Full Text] [Related]
26. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
27. p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India.
Saranath D; Tandle AT; Teni TR; Dedhia PM; Borges AM; Parikh D; Sanghavi V; Mehta AR
Oral Oncol; 1999 May; 35(3):242-50. PubMed ID: 10621843
[TBL] [Abstract][Full Text] [Related]
28. [PCR-SSCP and sequencing analysis on mutations of anti-oncogene p53 in asbestos-related lung cancer].
Fu D; Liu B; Miao Q; Wang H
Wei Sheng Yan Jiu; 1997 Sep; 26(5):289-92. PubMed ID: 10325638
[TBL] [Abstract][Full Text] [Related]
29. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
30. [Detection of point mutation of p53 gene in head and neck squamous cell carcinoma by non-isotopic PCR-SSCP].
Wang J; Huang H; Li J
Hua Xi Kou Qiang Yi Xue Za Zhi; 1997 Aug; 15(3):215-7. PubMed ID: 11480000
[TBL] [Abstract][Full Text] [Related]
31. Detection of loss of heterozygosity in the p53 tumor suppressor gene using a PCR-based assay.
Ridanpää M; Anttila S; Husgafvel-Pursiainen K
Pathol Res Pract; 1995 Jun; 191(5):399-402. PubMed ID: 7479357
[TBL] [Abstract][Full Text] [Related]
32. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus.
Sundaresan V; Ganly P; Hasleton P; Rudd R; Sinha G; Bleehen NM; Rabbitts P
Oncogene; 1992 Oct; 7(10):1989-97. PubMed ID: 1408139
[TBL] [Abstract][Full Text] [Related]
33. Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
van Puijenbroek M; Dierssen JW; Stanssens P; van Eijk R; Cleton-Jansen AM; van Wezel T; Morreau H
J Mol Diagn; 2005 Nov; 7(5):623-30. PubMed ID: 16258161
[TBL] [Abstract][Full Text] [Related]
34. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining.
Ryu JW; Lee MC; Jang WC
J Korean Med Sci; 2000 Feb; 15(1):73-7. PubMed ID: 10719813
[TBL] [Abstract][Full Text] [Related]
35. Correlation of allelic loss of the P53 gene and tumor grade, stage, and malignant progression in bladder cancer.
Tsutsumi M; Sugano K; Yamaguchi K; Kakizoe T; Akaza H
Int J Urol; 1997 Jan; 4(1):74-8. PubMed ID: 9179671
[TBL] [Abstract][Full Text] [Related]
36. A new polymorphic site in intron 2 of TP53 characterizes LOH in human tumors by PCR-SSCP.
Oliva MR; Saez GT; Latres E; Cordon-Cardo C
Diagn Mol Pathol; 1995 Mar; 4(1):54-8. PubMed ID: 7735557
[TBL] [Abstract][Full Text] [Related]
37. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.
Castresana JS; Rubio MP; Vázquez JJ; Idoate M; Sober AJ; Seizinger BR; Barnhill RL
Int J Cancer; 1993 Oct; 55(4):562-5. PubMed ID: 8104906
[TBL] [Abstract][Full Text] [Related]
38. Detection of loss of heterozygosity in tumor DNA samples by PCR.
Merlo GR; Cropp CS; Callahan R; Takahashi T
Biotechniques; 1991 Aug; 11(2):166-8, 170-1. PubMed ID: 1931011
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of loss of heterozygosity (LOH) at the p53 and Rb suppressor genes in urinary bladder carcinoma].
Tamada H; Suzuki Y; Tamura G
Nihon Hinyokika Gakkai Zasshi; 1994 May; 85(5):722-30. PubMed ID: 7912753
[TBL] [Abstract][Full Text] [Related]
40. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia.
Nishimura S; Asou N; Suzushima H; Okubo T; Fujimoto T; Osato M; Yamasaki H; Lisha L; Takatsuki K
Leukemia; 1995 Apr; 9(4):598-604. PubMed ID: 7723391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
